1. Introduction {#sec1}
===============

Cutaneous leishmaniasis (CL) is an infectious disease, transmitted by female sandflies, which presents high incidence and morbidity rates in developing countries, where access to health services is often precarious. This poverty related disease lead to great social and economic burden ([@bib2]). The World Health Organization estimates that global prevalence is approximately 12 million cases per year, occurring in 98 countries, but nearly 90% of the cutaneous and mucocutaneous cases are concentrated in seven developing countries, including Brazil ([@bib60]). Leishmaniasis is considered an important neglected tropical disease due to its extensive distribution in tropical areas of the globe and risk to produce deformities ([@bib44]).

Despite almost seven decades of researches assaying alternative therapies to replace pentavalent antimonials, these drugs remain the first-line treatment for most forms of leishmaniasis worldwide ([@bib61]). Pentavalent antimonials therapy is associated with mild to severe adverse effects, being often accompanied by pain and swelling at site of the intramuscular application and several systemic symptoms, which include nausea, vomiting, weakness and myalgia, abdominal colic, diarrhea, skin rashes and variable transient increase of transaminases and/or amylases ([@bib23]; [@bib38]). The most serious adverse effect associated with pentavalent antimonials therapy is undoubtedly cardiotoxicity, characterized by ventricular repolarization disorders (as alterations in T wave and ST segment) and arrhythmia, which can lead to sudden death ([@bib23]; [@bib38]). To date, the precise mechanism of action whereby pentavalent antimonials kill *Leishmania* parasites remains unknown. However, it seems to be multifactorial, as with other heavy metals, rather than being due to a single route ([@bib15], [@bib16]). At the molecular level, it is proposed that the antimonial react with sulfhydryl groups present in proteins, causing structural changes that would lead to an impairment of its function ([@bib16]). There is evidence that these compounds may inhibit certain phases of the energetic metabolism cycle of amastigotes. Experimental observations indicated that *in vitro* exposure of *L. (L.) mexicana* to sodium stibogluconate resulted in a dose-dependent reduction of both cellular viability and the production of CO~2~ from glucose and palmitate in parasite cultures ([@bib5]). Data indicate that the depletion of intracellular ATP levels is due to an inhibition of glycolytic enzymes and other components of the fatty acid pathway, but not from the hexose monophosphate pathway and the citric acid cycle ([@bib5]). Furthermore, studies have shown that the trivalent form (Sb^3+^) is able to cause inhibition of the trypanothione reductase activity in *L. (L.) donovani*, an essential enzyme for the parasite survival within macrophages, and it may be responsible for part of the leishmanicidal effects ([@bib4]; [@bib62]). Additional microbicidal mechanisms of antimonials might include: (i) induction of apoptosis in amastigotes by Sb^3+^, as observed by DNA fragmentation and phosphatidylserine exposure on the outer surface of the parasite plasma membrane ([@bib59]); (ii) inhibition of topoisomerases ([@bib31]); (iii) formation of complexes with ribonucleosides ([@bib13]); and (iv) interference in the translocation of preformed purines ([@bib11]).

The second-line drugs applied when antimonials cannot be resorted, amphotericin B and pentamidine isethionate present even higher toxicity and thus their use are only recommended in cases of contraindication, intolerance, low therapeutic response or resistance to antimonials ([@bib6]). These drugs are associated to a range of adverse effects, being the most serious nephrotoxicity, detected by a decreasing of glomerular filtration and insulin-dependent diabetes, respectively ([@bib20]; [@bib21]; [@bib46]). Additionally, other antileishmanial medicines such as paramomycin, miltefosine, pentoxifylline and ketoconazole are also available in some countries; however, some are still under clinical investigation ([@bib60]).

Drug combination therapy is a successful strategy in the treatment of several infectious diseases such as malaria, tuberculosis and AIDS, and has been applied for leishmaniasis treatment, mainly in endemic countries ([@bib46]; [@bib60]). Treatments using combined drugs have potential advantages, such as (i) shorten the course of treatment; (ii) decrease the risk of drug-resistant parasites; and, (iii) reduce the total dose of medicines needed, thereby decreasing both incidence of adverse effects and costs ([@bib9]; [@bib60]).

Approaches involving pentavalent antimonials associated to other drugs have been conducted, but some results are still controversial ([@bib3]; [@bib30]; [@bib33]; [@bib34]; [@bib35]). Even though combination therapies against visceral leishmaniasis produce cumulative or synergic effects that could reduce both parasite resistance and treatment failure ([@bib8]; [@bib22]), the therapeutic regimen must be based on the individual benefit/risk ratio of drugs, the infrastructure of the health service providing the treatment, the local availability of antileishmanial drugs and epidemiological issues ([@bib19]; [@bib60]).

For CL, topical treatment should be used as a first line treatment whenever possible, but in many cases of New World CL, systemic treatment might be indicated due to the risk of mucosal spread. Besides, the risk of severe adverse effects is acceptable for patients suffering from numerous, face-disfiguring or complicated lesions, but not for those with a mild form of the disease ([@bib9]; [@bib60]).

Naphtoquinones are natural compounds considered promising scaffolds for the development of new drugs, since they present many pharmacological activities including antibacterial ([@bib36]; [@bib54]), antifungal ([@bib24]; [@bib37]; [@bib58]), antiviral ([@bib27]; [@bib32]), antitumor ([@bib7]; [@bib10]; [@bib25]; [@bib28]; [@bib42]; [@bib47]), antimalarial ([@bib18]; [@bib52]; [@bib55]) and antileishmanial activities ([@bib29]; [@bib53]). Examples of 1,4-naphthoquinones that showed activity against species of *Leishmania* and *Trypanosoma cruzi* are lapachol, isolated from Brazilian trees belonging to the *Tabebuia* genus, and its derivatives α-lapachone and β-lapachone ([@bib14]; [@bib26]). However, lapachol and several of its derivatives exhibited significant toxicity, therefore presenting an obstacle for clinical treatment. In order to develop less toxic derivatives for mammalian cells, the chemical modification of the quinonoid center of α-lapachone and 2-hydroxy-1,4-naphthoquinone (lawsone), followed by epoxidation, generating the oxiranes epoxy-α-lapachone (LAP) and epoxymethyl-lawsone (LAW) respectively. Recently, we have demonstrated that LAP and LAW ([Fig. 1](#fig1){ref-type="fig"}), were effective against *Leishmania* in both *in vitro* and *in vivo* experimental infections and showed low toxicity for mammalian cells ([@bib39]; [@bib56], [@bib57]).Fig. 1Chemical structure of tested drugs. (A) 2,2-dimethyl-3,4-dihydrospiro\[benzo\[g\]chromene-10,2′-oxiran\]-5-one, also known as epoxy-α-lapachone (C~16~H~16~O~3~, 256.296 g/mol; CID 12000280) (<https://pubchem.ncbi.nlm.nih.gov/compound/12000280#section=Top>), (B) 2-methoxy-4*H*-spiro\[naphthalene-1,2′-oxiran\]-4-one, also known as epoxymethyl-lawsone (C~12~H~10~O~3~, 202.21 g/mol), and (C) meglumine antimoniate known commercially as Glucantime (C~7~H~18~NO~8~Sb, 365.98 g/mol) (Adapted from [@bib16]).Fig. 1

LAP led to a dose- and time-dependent decrease in the growth rate of *Leishmania (Viannia) braziliensis* and *L. (L.) amazonensis* promastigote cultures, killed amastigotes inside human macrophages ([@bib56]), and reduced the mean lesion size in BALB/c mice infected by *L. (L.) amazonensis* ([@bib57]). LAW affected promastigotes viability after 24 h of exposure and demonstrated an activity on intracellular amastigotes similar to the reference drug meglumine antimoniate. LAW was also able to hinder lesion growth in *L. (L.) amazonensis* infected BALB/c mice ([@bib39]).

Studies aim to identify promising leishmanicidal drug associations with high activity in experimental infection, since it may lead to improved treatment efficacy of treatments and/or reduce dose regimen and toxicity ([@bib17]; [@bib45]). Thereby, following this research line, the objective of the present study is to determine potential of the combination therapy using meglumine antimoniate (MA) associated with epoxy-α-lapachone or epoxymethyl-lawsone against experimental infection. Herein, we demonstrate an enhanced leishmanicidal effect produced by such combination treatments on *L. (L.) amazonensis*, either in macrophage cultures infected by this parasite or in experimentally challenged BALB/c mice.

2. Material and methods {#sec2}
=======================

2.1. Chemicals and culture reagents {#sec2.1}
-----------------------------------

Dimethyl sulfoxide (DMSO), penicillin, streptomycin, Lab-Tek chamber slides, Greiner CELLSTAR™ 96 well plates, RPMI 1640 medium and Schneider\'s Drosophila medium were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Fetal calf serum (FCS) was acquired from Cultilab S/A (Brazil). CellTiter-Glo™ luminescent cell viability assay and GoTaq™ qPCR Master Mix were purchased from Promega Corporation (USA). Meglumine antimoniate (Glucantime™) was kindly provided by Dr. Armando de Oliveira Schubach team (INI/Fiocruz). Propylene glycol was purchased from Vetec Quimica. Epoxy-α-lapachone and epoxymethyl-lawsone compounds were synthesized by the Department of Organic Chemistry of the Instituto de Química, Universidade Federal Fluminense.

2.2. Cell culture {#sec2.2}
-----------------

Peritoneal macrophages were removed from BALB/c mice as previously described ([@bib39]) and recovered in RPMI 1640 medium containing 10% FCS by centrifugation (2 × , 1.800×*g*, 10 min, 4 °C). After, cells were seeded in Lab-Tek chamber slides at a density of 5 × 10^5^ cells/well and incubated (37 °C, 5% of CO~2~) for 24 h. Adherent macrophages were used in the cytotoxicity and parasite infection assays.

2.3. Parasite cultures {#sec2.3}
----------------------

Promastigotes of *Leishmania (Leishmania) amazonensis* (strain MHOM/BR/73/LTB0016) were obtained from the Leishmania collection (Coleção de Leishmania do Instituto Oswaldo Cruz -- CLIOC) of the Instituto Oswaldo Cruz (Fiocruz). Cell cultures were maintained at 28 °C in Schneider\'s medium (pH 7.2) containing 1 mM L-glutamine, 10% FCS, 100 IU/mL penicillin, and 100 μg/mL streptomycin. Subpassages were made to maintain the parasites in the logarithmic growth phase.

2.4. Activity against intracellular amastigotes {#sec2.4}
-----------------------------------------------

Macrophages were co-incubated (4 h, 37 °C) with promastigotes in a proportion of 5:1 (parasite:cell) in Lab-Tek chamber slides, followed by washing with PBS and addition of RPMI medium containing 5% FCS. After, cultures were incubed (37 °C, 24 h) with meglumine antimoniate, epoxy-α-lapachone and epoxymethyl-lawsone in monotherapy at the concentrations corresponding to its IC~50~ values previously determined (2.0 μM, 5.0 μM and 7.5 μM, respectively), and in combinations of MA:LAP or MA:LAW in fixed ratios 3:1, 1:1, 1:3, where 3:1 refers to 3 parts of MA IC~50~ value with 1 part of LAP IC~50~ or LAW IC~50~ value (75% of MA + 25% of LAP or LAW = total dose). Similarly, 1:1 and 1:3 ratios correspond to 1 part of MA IC~50~ plus LAP IC~50~ or LAW IC~50~ (50%: 50%), and 1 part of MA IC~50~ plus 3 parts of LAP IC~50~ or LAW IC~50~ (25%: 75%), respectively. Then, slides were fixed with 100% methanol and Giemsa-stained. The endocytic index was determined by counting intracellular parasites in at least 300 random cells. The results are expressed as the mean and standard deviation of three independent assays.

2.5. Toxicity of compounds and its combinations to BALB/c mice macrophages {#sec2.5}
--------------------------------------------------------------------------

Macrophages seeded on 96-well plates (2 × 10^5^ per well) were exposed (37 °C, 72 h) to meglumine antimoniate, epoxy-α-lapachone and epoxymethyl-lawsone in monotherapy at a concentration equivalent to half of IC~50~ previously defined (2.0 μM, 5.0 μM and 7.5 μM, respectively) and in combinations that followed the ratio 3 : 1, 1 : 1 and 1 : 3, as described above. Then, macrophages viability was determined by addition of CellTiter-Glo™ (20μL/well) and incubation (25 °C, 3 min) under agitation. Luminescence was measured using a FlexStation 3 reader (Molecular Devices, Sunnyvale, CA, USA).

2.6. Experimental murine infection {#sec2.6}
----------------------------------

BALB/c mice with 5- to 7-week-old weighing approximately 22 g were inoculated in the footpad of the left hind limb with 1.0 × 10^5^ promastigotes of *L. (L.) amazonensis* in the stationary growth phase in a total volume of 50 μL diluted in 10 mM of phosphate-buffered saline pH 7.2 (PBS).

2.7. Mice treatment schedules {#sec2.7}
-----------------------------

To determine doses to be applied in the combination assays, BALB/c mice were previously treated (five animals per group) with three different doses of each drug, defined here as low, intermediate and high dose, as follow: meglumine antimoniate (0.23 mg of Sb^5+^/Kg/day, 2.27 mg of Sb^5+^/Kg/day and 22.7 mg of Sb^5+^/Kg/day); epoxy-α-lapachone (0.23 mg/kg/day, 2.27 mg/kg/day and 22.7 mg/kg/day); and epoxymethyl-lawsone (0.11 mg/kg/day, 1.14 mg/kg/day and 11.4 mg/kg/day), starting six weeks after infection, as previously described ([@bib57]; [@bib39]). Briefly, oxiranes were diluted in a mixture of DMSO: propylene glycol: saline (1 : 12: 7) because of their low solubility in water, then drugs were administrated daily by subcutaneous route (100 μL per animal), from Monday to Friday until 20 doses. Negative-control group was treated with vehicle used to dissolve the oxirane compounds. The lesions were evaluated weekly by measuring the height and width of the paw, and lesion volumes were obtained by multiplying these measures in mm^3^ with a digital caliper. The intermediate doses of each drug were selected as its efficacy was similar to a high dose. Meglumine antimoniate, epoxy-α-lapachone and epoxymethyl-lawsone were tested in monotherapy (2.27 mg of Sb^5+^/Kg/day, 2.27 mg/kg/day and 1.14 mg/kg/day, respectively) and in combinations following fixed-proportion of 3 : 1; 1 : 1 and 1 : 3, as already described in 2.4.

2.8. Parasite kinetoplast DNA quantification by real-time PCR (qPCR) {#sec2.8}
--------------------------------------------------------------------

DNA from the footpad and draining lymph nodes of 3 animals per group were extracted following a standard phenol/chloroform protocol ([@bib50]). DNA was quantified in a NanoDrop 2000c spectrophotometer (ThermoScientific) and diluted to 10 ng/μL of total DNA. Real time PCR was performed in QuantStudio™ 3 Real Time PCR System equipment using fast cycle with GoTaq™ qPCR Master Mix, 2  μL of DNA sample at a final volume of 10 μL. Primers were target for the parasite kDNA1 (forward: 5′-GGGTAGGGGCGTTCTGC-3′, reverse: 5′-TACACCAACCCCCAGTTTGC-3'; accession number: M94088), and mouse β-actin (forward: 5′-AGAGGGAAATCGTGCGTGAC-3′, reverse: 5′-CAATAGTGATGACCTGGCCGT-3'; accession number: X03672) was used as an endogenous control. Parasite load was estimated from a standard curve (1.7 × 10^−1^ to 1.7 × 10^4^ parasites) of known amounts of *Leishmania* parasite obtained from *in vitro* culture, considering size of the genome sequence of *L. (L.) amazonensis* and kinetoplast DNA replication ([@bib51]; [@bib49]; [@bib1]).

2.9. Ethical aspects {#sec2.9}
--------------------

Mice experimental procedures performed here were approved by the Committee for the Ethical Use of Animals of Instituto Oswaldo Cruz (L-052/2015). The animals were obtained from the Instituto de Ciência e Tecnologia em Biomodelos -- Fiocruz.

2.10. Statistical analysis {#sec2.10}
--------------------------

Mann-Whitney, one-way ANOVA tests (Bonferroni post-test and Tukey HSD) were applied to compare results and data matrices were considered statistically different when the P value was less than 0.05. Statistical analyses were performed using GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA) and R software version 3.5.2.

3. Results and discussion {#sec3}
=========================

Leishmaniases represent a major public health issue in the Americas due to their distribution in several countries and high prevalence ([@bib43]). Treatment is a pivotal step to control the disease; however, effectiveness of current options has been questioned due to the increasing numbers of resistance and toxicity, pointing toward the need of novel drugs ([@bib12]). In recent years, efforts have been performed to improve antimonial chemotherapy. Several studies added further information on its chemical structure ([@bib15]), mechanisms of action, new methods of preparation and potential incorporation into different formulations (reviewed in [@bib16]). In this context, a promising strategy is the association of pentavalent antimonials with oxiranes, compounds that showed significant antileishmanial activity; such association could reduce drug doses and toxicity, while maintain or improve the baseline efficacy of pentavalent antimonials. In addition, a combination of two drugs with rather different mechanisms of action over the parasites may have the benefit of hindering the emergence of resistant strains. Therefore, we devised in the present study a new approach for the CL chemotherapy based on the combination treatment of meglumine antimoniate with epoxy-α-lapachone or epoxymethyl-lawsone.

3.1. Effects of drug combinations against intracellular amastigotes of *Leishmania (L.) amazonensis* {#sec3.1}
----------------------------------------------------------------------------------------------------

Initially, we investigated the combination effects of MA with oxiranes LAP and LAW on peritoneal macrophages of BALB/c mice infected *in vitro* with *L. (L.) amazonensis*. The drugs were tested alone (at a concentration equivalent to half of IC~50~ values previously determined) or in combinations following fixed-ratios of 3 : 1; 1 : 1 and 1 : 3. All drugs as well as its combinations exhibited impact over the macrophage-infecting parasites, as determined by the endocytic index (EI): treated cultures had EI values lower than untreated cultures ([Fig. 2](#fig2){ref-type="fig"}). The effects of MA or LAW monotherapy on parasites showed similar values; the EI was reduced 82% and 80%, respectively. LAP alone showed the lowest impact over the parasites (EI reduced 75%). Some of the drug combinations were sensibly more effective over the intracellular parasites: MA/LAP or MA/LAW at 3 : 1 ratio led to 98.3% and 93.6% reduction on the EI of the control, respectively. In relation to respective drugs alone, the ratio combinations showed reductions of 90.5% and 93.2% (MA/LAP) and 64.6% and 67.7% (MA/LAW). No significant difference in 1:3 and 1:1 ratios were detected. Cytotoxicity assays performed using either the drugs monotherapy or its combinations, with ratios established above, indicated no significant change in the viability of treated macrophage cultures when compared to untreated controls. Control groups were cultivated with medium only or 0.8% DMSO, used as solvent for compounds, (data not shown). This set of results established the feasibility of proceeding to *in vivo* experiments, aiming to analyze the effects of combination treatments on the progression of lesions in experimentally challenged mice.Fig. 2Effects of combination treatments with epoxy-α-lapachone and meglumine antimoniate (A) and epoxymethyl-lawsone and meglumine antimoniate (B) on the endocytic index in peritoneal murine macrophages infected *in vitro* with *Leishmania (L.) amazonensis*. Cultures of peritoneal macrophages isolated from BALB/c mice were infected with *L. (L.) amazonensis* and incubated (24 h, 37 °C) with either meglumine antimoniate (MA), epoxy-α-lapachone (LAP) or epoxymethyl-lawsone (LAW) in monotherapy at the concentrations corresponding to its IC~50~ values previously determined (2.0 μM, 5.0 μM and 7.5 μM, respectively), and in combinations of MA: LAP \[3 : 1 (1.5 μM + 1.25 μM), 1 : 1 (1.0 μM + 2.5 μM), 1 : 3 (0.5 μM + 3.75 μM)\] and MA: LAW in fixed ratios \[3 : 1 (1.50 μM + 1.88 μM), 1 : 1 (1.0 μM + 3.75 μM), 1 : 3 (0.5 μM + 5.63 μM)\]. Control cultures (white bars) were treated with 0.8% DMSO. The data are expressed as the mean and standard deviation (±) of three independent assays. Difference between groups was analyzed with one-way ANOVA, Bonferroni post-test and Tukey HSD. (\#) Statistically significance between control and treated groups (p ≤ 0.001). (\*\*\*) Difference between treated groups and the most active combination (3:1) (p ≤ 0.001).Fig. 2

Previous data from our research group indicated that treatment of BALB/c mice challenged with *L. (L.) amazonensis* with either MA, LAP and LAW (in three distinct dosages) led to a measurable reduction in the mean size of parasite-associated lesions, pointing to a control of the *in vivo* infection. The tenth week post-infection was settled as the chosen time point for lesion size measurements. Considering that no dose-response pattern was observed for any of the applied dosages of LAW and LAP and that the highest dosage of these compounds elicited significant signs of tissue toxicity ([@bib40]), the intermediate dosage was elected to perform the combination treatment assays.

3.2. Effects of drug combinations treatment on experimental cutaneous lesions caused by *Leishmania (L.) amazonensis* {#sec3.2}
---------------------------------------------------------------------------------------------------------------------

As previously observed, the administration of MA, LAP or LAW prevented lesion development, leading to a reduction in mean lesion size in treated challenged mice when compared to untreated animals after the fourth week of treatment. Similar results were observed in mice treated with combinations of the compounds ([Fig. 3](#fig3){ref-type="fig"}A and C). The mean lesion volume measured in untreated animals 10 weeks post-infection was 10.7 ± 1.25 mm^3^. MA presented the lowest effect on reducing mean lesions size, leading to a 30% decrease in lesions size, whereas both LAP and LAW monotherapy presented better effects, decreasing 40% of lesions size ([Fig. 3](#fig3){ref-type="fig"}B and D). Results of drug combination revealed a better profile of MA/LAP or MA/LAW at 3 : 1 ratio (75% of MA and 25% of LAP or LAW) achieving a lesion reduction of 61.7 and 54.4%, respectively. Collectively this data indicates that oxiranes potentiate the leishmanicidal effects of MA. Additionally, the combination of MA/LAW at 1 : 3 ratio also presented statistical difference compared to MA monotherapy ([Fig. 3](#fig3){ref-type="fig"}D).Fig. 3Treatment of mice challenged with *Leishmania (L.) amazonensis*. BALB/c mice were treated daily with meglumine antimoniate (MA), epoxy-α-lapachone (LAP) or epoxymethyl-lawsone (LAW) in monotherapy at doses previously defined (2.27 mg of Sb^5+^/Kg/day; 2.27 mg/kg/day and 1.14 mg/kg/day, respectively), and in combinations of MA: LAP \[3:1 (1.70 mg + 0.57 mg), 1 : 1 (1.14 mg + 1.14 mg) and 1 : 3 (0.57 mg + 1.70 mg)\] and MA: LAW \[3:1 (1.70 mg + 0.29 mg), 1 : 1 (1.14 mg + 0.57 mg) and 1 : 3 (0.57 mg + 0.86 mg)\]. Treatments were administrated daily until 20 doses and lesion sizes (mm^3^) were measured weekly (A and C). The results are represented as mean and standard deviation (±) from three independent experiments. The endpoint was on the 10th week and the differences (%) of each treatment are shown (C and D). Difference between groups was analyzed using Mann-Whitney test. \*Statistically significant p ≤ 0.05, \*\*Statistically significant p ≤ 0.01 and \*\*\*Statistically significant p ≤ 0.001.Fig. 3

3.3. Parasite kinetoplast DNA quantification in footpad and lymph nodes of treated mice {#sec3.3}
---------------------------------------------------------------------------------------

The effectiveness of the drugs and its combinations in experimental cutaneous leishmaniasis was also evaluated by measuring the parasite kinetoplast DNA (kDNA) quantification from footpad and lymph nodes after the last week of treatment (tenth week) by a quantitative real-time PCR (qPCR) assay ([Fig. 4](#fig4){ref-type="fig"}). The performance of the qPCR for *Leishmania* kDNA quantification was related with the presence of parasite in the lesion sites and lymph nodes and defined here as parasite load. The results show significant decrease of parasite load in footpad lesion and lymph nodes for all treatment modalities compared to control. LAP, LAW and MA treatments presented similar parasite load reductions in footpad (65.22, 69.75, and 84.25%) and in lymph nodes (74.59, 81.54, and 79.09%).Fig. 4Parasite load in footpad lesion and lymph node in BALB/c mice. Animals infected with *Leishmania (L.) amazonensis* were treated or not (control) with oxiranes epoxy-α-lapachone (LAP) or epoxymethyl-lawsone (LAW) and meglumine antimoniate alone or in combinations at fixed-ratio of 3:1, 1 : 1 and 1 : 3. The *Leishmania* kDNA were quantified by real-time PCR (qPCR) assay. Parasite load quantification was performed in footpad (A and C) and lymph nodes (B and D) at the endpoint of 10 weeks of treatment. The results are expressed (parasite load/20 ng total DNA) as the mean and standard deviation of three independent assays. Difference between groups was analyzed using Mann-Whitney test. \*Statistically significant p ≤ 0.05, \*\*Statistically significant p ≤ 0.01 and \*\*\*Statistically significant p ≤ 0.001.Fig. 4

Although both treatment combinations showed a statistically significant reduction in relation to the control, MA with LAP showed the best results in the reduction of footpad lesion parasite load compared to MA and LAW combination. MA/LAP at 1 : 1 and at 1 : 3 ratios exhibited highest parasite elimination (96.81 and 96.65%), presenting significant decrease in relation to the drugs alone (p \< 0.001). Further, kDNA-qPCR analysis of the mice lymph nodes showed that the treatment with drugs, as well as its combinations, was effective in eliminating parasites in these areas when compared to the control group. However, no significant difference among groups was detected (p \> 0.05).

The search for new drugs to treat leishmaniasis is still incipient. Drug development faces many obstacles and new drug candidates against CL often did not progress further to clinical trials. The few advances so far are limited to the development of new formulations for clinical available drugs or drug repurposing ([@bib41]). Despite the high incidence of adverse effects and the increasing numbers of unresponsive strains, pentavalent antimonials remain the basis of chemotherapy and in short-term there is no perspective of new chemical entity or formulation approval ([@bib41]).

Enhancement of effects due to combination therapies can occur basically in two ways: (*i*) one drug may increase the activity of the other, or (*ii*) the effect of two drugs may combine to produce an activity distinct to that observed for each one individually ([@bib48]). The global increment in leishmancidal activity observed for treatment with MA/LAP or MA/LAW at 3:1 ratio, considering the reduction of lesion size was not confirmed by parasite load quantification. According to this measurement, the best results related to combination treatment were found in MA/LAP at 1 : 1 and 1 : 3 ratio. The decrease of the parasitic kDNA in lymphatic nodes of all treated animals confirms the systemic leishmanicidal effect of the oxiranes tested. However, differences among its combinations with reference drug MA were not possible to demonstrate. Although the direct toxic effect of these compounds on *Leishmania* parasite is well documented ([@bib39]; [@bib56], [@bib57]), the possibility that their action is also related to the modulation of cells or components of the immune system may not be discarded.

This work showed an additive effect of the combined treatment between oxiranes and meglumine antimoniate that can be exploited, since these drugs present marked structural differences, which ensure distinct mechanisms of action, and may enhance their individual effects; however, further studies to detect synergistic effects between drugs are needed.

The combination treatments proposed here may represent a new alternative for leishmaniasis chemotherapy, keeping the first-line drugs, but with possible reduction in both the incidence of adverse effects and risk of emergence of antimonial-unresponsive strains.

4. Conclusions {#sec4}
==============

The results presented herein indicate that the association of meglumine antimoniate with oxiranes may lead to an increment of global antileishmanial potential *in vitro* and *in vivo*, as compared to the use of these compounds individually. Thereby, this strategy may be a new approach for the cutaneous leishmaniasis treatment. Finally, we emphasize the need for further studies to thoroughly understand the basis of the effects of such combinations.
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